查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1451899

仿製药市场：2024-2032 年全球产业趋势、份额、规模、成长、机会与预测

Generic Oncology Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

2023年全球肿瘤仿製药市场规模达293亿美元。展望未来， IMARC Group预计到2032年市场规模将达到459亿美元，2024-2032年复合年增长率（CAGR）为4.98%。由于过度吸烟和饮酒导致癌症患病率不断上升，对开发新药的研究投资不断增加，以及对简化药品生产流程的严格法规的执行日益严格，推动该市场正在稳步增长。

仿製药市场分析：

市场成长与规模：在癌症盛行率不断上升以及对具有成本效益的治疗方案的需求不断增长的推动下，仿製药市场正在经历稳定增长。

主要市场驱动因素：主要驱动因素包括癌症盛行率上升、品牌肿瘤药物的专利到期、政府控制医疗成本的措施以及药品製造技术的进步。

技术进步：持续创新正在增强品质控制、简化製造流程以及改善仿製药的配方和给药系统。

产业应用：仿製药主要用于各种癌症类型的癌症治疗，使其成为癌症治疗的重要组成部分。它们提供具有成本效益的品牌药物替代品，增加患者的可近性。

主要市场趋势：主要趋势包括肿瘤学中越来越多地采用生物相似药、个人化医疗方法以及远距医疗和远距医疗保健服务对药物输送的影响。这些趋势反映了不断变化的患者需求和医疗保健实践。

地理趋势：由于癌症盛行率高、监管框架严格以及对成本控制的重视，北美地区的仿製药市场呈现显着成长。由于医学研究业务投资的增加，亚太地区也出现了重大发展。

竞争格局：市场竞争格局为多家製药公司积极从事肿瘤学仿製药的研发和生产。策略伙伴关係和收购是加强市场地位的常见策略。

挑战与机会：挑战包括应对复杂的监管流程、确保产品品质和安全以及应对竞争。然而，这些挑战也为扩大产品组合、满足个人化癌症治疗的需求以及进入医疗保健需求未满足的新兴市场提供了机会。总体而言，市场为能够有效应对这些挑战的参与者提供了巨大的成长潜力。

仿製药市场趋势：

癌症病例增加

全球癌症病例的增加是推动市场成长的关键因素之一。癌症诊断的增加正在导致製药业内的一系列发展和变革，特别是在仿製药领域。这些由癌症发病率上升所推动的转变是多方面的，具有深远的影响，有助于提高非专利肿瘤药物的可及性和有效性。随着癌症成为发病率和死亡率的主要原因，提供具有成本效益且可靠的治疗方案至关重要。肿瘤学仿製药通常比品牌药更实惠，非常适合满足这一需求，并为不同社会经济背景的患者提供易于使用的解决方案。它们的经济性和可近性使它们成为对抗癌症不可或缺的工具，确保患者得到及时和充分的照顾。医疗保健系统压力的缓解提高了癌症治疗的整体效率和效果，最终使患者受益。

政府措施和法规

政府监管机构负责监督仿製药肿瘤药物的审批和市场准入。他们制定了严格的标准，在批准之前评估这些药物的安全性和有效性。这些标准对于确保仿製药成为品牌药的可靠且有效的替代品至关重要。与专利到期和市场独占期相关的政府政策显着影响仿製药的可用性。当品牌肿瘤药物的专利到期时，监管机构可能会批准仿製药进入市场。这个过程以法律框架为指导，鼓励製药业的竞争和可负担性。监管机构负责监督药物警戒计划，以监测和评估仿製药上市后的安全性。这些机构也执行品质控制标准，以维持药物品质和纯度的一致性，确保患者接受安全有效的治疗。此外，各国管理机构正在提供研究资助或税收优惠等激励措施，以鼓励製药公司投资仿製药的开发。

製造技术进步

仿製药生产的不断进步正在支持市场的成长。连续製造和即时监控系统等先进製造技术正在改善仿製药的品质控制。这些系统使製药公司能够保持一致的产品质量，降低影响患者治疗结果的变化风险。这种增强的品质保证增强了人们对仿製药有效性的信心。自动化和机器人技术正在简化仿製药的製造流程。效率的提高可以提高这些药物的产量、降低生产成本并加快上市时间。技术进步也扩大了製造业务的可扩展性。这使得仿製药製造商能够根据市场需求更灵活地调整产量。药物配方和输送系统的进步正在促进创新仿製药肿瘤药物产品的开发。这些技术有潜力提高药物疗效、减少副作用并提高患者依从性，所有这些都是癌症治疗的关键因素。

专利到期和具有成本效益的解决方案

几种品牌肿瘤药物的专利到期为仿製药製造商带来了机会。当创新癌症疗法的专利到期时，仿製药製造商可以进入市场，提供成本更低的替代品。这种竞争不仅减轻了病患的经济负担，也有助于控制医疗成本。负担得起的仿製药肿瘤药物的可用性确保更多患者能够获得治疗，从而推动市场成长。

监管支持和批准途径

监管机构正在实施仿製药的快速审批途径。此外，各种政府措施和政策鼓励仿製药的开发和生产。这些监管支持为仿製药製造商创造了有利的环境。一些监管机构也为仿製药肿瘤药物的审查和批准提供快速途径，特别是当需要加强竞争或相关药物来解决未满足的医疗需求时。这些途径旨在简化审批流程并促进及时进入市场。仿製药製造商可能会面临来自寻求扩大其独占权的创新公司的专利挑战。专利诉讼和挑战在监管环境中发挥重要作用，因为专利纠纷的解决可以影响仿製药市场进入的时间。

个性化医疗的需求

基因组学和生物标记研究的进步使得人们能够更深入地了解癌症的分子机制。这些知识可以识别与不同类型癌症相关的特定基因改变和生物标誌物，为标靶治疗的开发铺平道路。肿瘤学中的个人化医疗通常涉及使用标靶疗法，旨在根据特定的分子特征选择性地抑制癌细胞的生长或存活。随着品牌标靶疗法面临专利到期，仿製药不断涌现，以提供具有成本效益的替代方案，扩大个人化治疗选择的范围。伴随诊断与个人化医疗的整合日益受到重视。伴随诊断有助于识别最有可能对特定治疗产生反应的患者，使医疗保健提供者能够根据患者独特的基因谱量身定制治疗干预措施。通用肿瘤药物可以与伴随诊断一起开发，以提高治疗效果。

医疗保健成本控制

政府和医疗保健提供者越来越关注成本控制策略。使用非专利肿瘤药物有助于降低整体医疗成本，使癌症治疗对于医疗保健系统更具可持续性。医疗保健（包括肿瘤治疗）成本的不断增加对于许多医疗保健系统来说变得不可持续。此外，随着癌症盛行率的上升和创新疗法的出现，越来越需要寻找具有成本效益的解决方案。肿瘤学仿製药通常比品牌药更便宜，在控制整体医疗保健支出方面发挥着至关重要的作用。政府和医疗保健支付者正在实施促进使用仿製药的政策，作为节省成本的措施。仿製药替代，即仿製药取代品牌药，正积极鼓励降低癌症治疗的成本。在肿瘤学领域，这可以节省大量成本，特别是在处理高成本生物製剂时。仿製药的进入给品牌药带来了定价压力。随着仿製药替代品的出现，竞争往往会导致仿製药和品牌药物的价格下降。这不仅有利于患者，也支持医疗保健成本控制措施。

对仿製药的接受度不断提高

对仿製药的接受度不断提高正在支持市场的成长。患者和医疗保健系统都受益于仿製药提供的经济优势，使基本药物变得更便宜。临床研究和现实世界的证据支持仿製药与品牌药的表现相当的观点。随着越来越多的证据积累，医疗保健专业人员和患者对仿製药的有效性越来越有信心。仿製药的可用性正在扩展到各个治疗领域，从心血管疾病和糖尿病等慢性疾病到急性疾病和传染病。更广泛的仿製药组合有助于提高接受度，因为它涵盖了广泛的医疗需求。除此之外，提高健康素养和教育患者了解仿製药的努力正在提高仿製药的接受度。当患者了解仿製药具有与品牌药相同的品质和功效时，他们更有可能接受仿製药作为可行的治疗选择。此外，生物相似药（高度相似的生物药物版本）的出现正在得到各个地区的监管支持。这种支持增强了人们对生物相似药安全性和有效性的信心，有助于它们作为昂贵生物製剂的替代品被接受。

市场整合与策略合作

併购正在成为寻求巩固其在仿製药市场地位的公司的重要策略。大型製药公司经常收购规模较小的製药公司，以获得其产品组合、製造能力或研究管道。此次合併提高了营运效率并增强了收购实体的整体竞争力。合作和伙伴关係使公司能够汇集资源和专业知识，加速仿製药的研发 (R&D)。透过结合知识和利用优势，公司可以更有效地将新的和改进的仿製药配方推向市场。这对于及时引入具有成本效益的替代方案至关重要的行业至关重要。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球仿製药市场

  • 市场概况
  • 市场业绩
  • 市场区隔：按地区
  • 市场预测

第 6 章：全球仿製药市场

  • 市场概况
  • 市场走向
  • COVID-19 的影响
  • 顶级非专利肿瘤药物
  • 价格分析
  • 市场预测
  • SWOT分析
    • 概述
    • 优势
    • 弱点
    • 机会
    • 威胁
  • 价值链分析
    • 研究与开发
    • 製造业
    • 行销
    • 分配
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
    • 仿製药产业的法规
  • 主要市场驱动因素与成功因素

第 7 章：全球仿製药市场：主要地区表现

  • 北美洲
  • 欧洲
  • 亚太地区
  • 中东和非洲
  • 拉丁美洲

第 8 章：全球仿製药市场：竞争格局

  • 市场结构
  • 市场区隔：按关键参与者
  • 主要球员简介

第 9 章：仿製药肿瘤药物生产流程

  • 产品概述
  • 详细製程（片剂）
  • 详细製程（注射）
  • 涉及的各种类型的单元操作
  • 质量平衡和原料要求

第 10 章：专案细节、要求与涉及的成本

  • 土地需求和支出
  • 建设需求及支出
  • 工厂机械
  • 机械图片
  • 原料需求及支出
  • 包装要求及费用
  • 交通需求及支出
  • 公用事业要求和支出
  • 人手需求及开支
  • 其他资本投资

第 11 章：贷款与经济援助

第 12 章：专案经济学

  • 专案资本成本
  • 技术经济参数
  • 供应链各层面的产品定价与利润
  • 税金和折旧
  • 收入预测
  • 支出预测
  • 财务分析
  • 利润分析
Product Code: SR112024A545

The global generic oncology drugs market size reached US$ 29.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 45.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.98% during 2024-2032. The market is experiencing steady growth driven by the growing prevalence of cancer due to excessive smoking of tobacco products and consumption of alcohol, rising investments in research operations for developing novel drugs, and increasing implementation of stringent regulations for streamlining drug production process.

Generic Oncology Drugs Market Analysis:

Market Growth and Size: The generic oncology drugs market is experiencing stable growth, driven by the increasing cancer prevalence and the growing demand for cost-effective treatment options.

Major Market Drivers: Key drivers include the rising cancer prevalence, patent expirations of branded oncology drugs, government initiatives to control healthcare costs, and advancements in pharmaceutical manufacturing technologies.

Technological Advancements: Continuous innovations are leading to enhanced quality control, streamlined manufacturing processes, and improved formulation and delivery systems for generic oncology drugs.

Industry Applications: Generic oncology drugs are primarily used in cancer treatment across various cancer types, making them a vital component of cancer care. They offer cost-effective alternatives to branded drugs, increasing patient accessibility.

Key Market Trends: Key trends include the growing adoption of biosimilars in oncology, personalized medicine approaches, and the influence of telemedicine and remote healthcare services on drug delivery. These trends reflect evolving patient needs and healthcare practices.

Geographical Trends: The North America region exhibits significant growth in the generic oncology drugs market due to the high cancer prevalence, stringent regulatory frameworks, and emphasis on cost containment. Asia Pacific is also witnessing significant developments on account of rising investments in medical research operations.

Competitive Landscape: The market features a competitive landscape with multiple pharmaceutical companies actively engaged in research and development (R&D) and manufacturing of generic oncology drugs. Strategic partnerships and acquisitions are common strategies to strengthen market positions.

Challenges and Opportunities: Challenges include navigating complex regulatory processes, ensuring product quality and safety, and addressing competition. However, these challenges also present opportunities for expanding product portfolios, meeting the demand for personalized cancer treatments, and entering emerging markets with unmet healthcare needs. Overall, the market presents significant growth potential for players who can navigate these challenges effectively.

Generic Oncology Drugs Market Trends:

Increasing Cases of Cancer

The increasing cases of cancer around the world represent one of the crucial factors impelling the growth of the market. This rise in cancer diagnoses is leading to a series of developments and transformations within the pharmaceutical industry, particularly in the domain of generic oncology drugs. These transformations, driven by the heightened cancer incidence, are multifaceted and have far-reaching implications that contribute to the accessibility and effectiveness of generic oncology drugs. With cancer emerging as a leading cause of morbidity and mortality, the availability of cost-effective and reliable treatment options is paramount. Generic oncology drugs, often more affordable than their branded counterparts, are ideally positioned to meet this demand and provide accessible solutions for patients across diverse socioeconomic backgrounds. Their affordability and accessibility make them indispensable tools in the fight against cancer, ensuring that patients receive timely and adequate care. This alleviation of healthcare system pressures enhances the overall efficiency and effectiveness of cancer treatment, ultimately benefiting patients.

Government Initiatives and Regulations

Government regulatory agencies oversee the approval and market entry of generic oncology drugs. They establish rigorous standards to evaluate the safety and efficacy of these medications before granting approval. These standards are critical in ensuring that generic drugs are reliable and effective alternatives to their branded counterparts. Government policies related to patent expiration and market exclusivity periods significantly impact the availability of generic oncology drugs. When patents for branded oncology drugs expire, regulatory agencies may grant approval for generic versions to enter the market. This process is guided by legal frameworks, which encourage competition and affordability in the pharmaceutical industry. Regulatory agencies oversee pharmacovigilance programs to monitor and assess the safety of generic oncology drugs once they are on the market. These agencies also enforce quality control standards to maintain the consistent quality and purity of medications, ensuring that patients receive safe and effective treatments. Moreover, governing agencies of various countries are providing incentives, such as research grants or tax benefits, to encourage pharmaceutical companies to invest in the development of generic oncology drugs.

Technological Advancements in Manufacturing

The rising advancements in the manufacturing of generic oncology drugs are supporting the market growth. Advanced manufacturing technologies, such as continuous manufacturing and real-time monitoring systems, are improving the quality control of generic oncology drugs. These systems enable pharmaceutical companies to maintain consistent product quality, reducing the risk of variations that can impact patient outcomes. This enhanced quality assurance instils confidence in the effectiveness of generic drugs. Automation and robotics are streamlining the manufacturing processes of generic oncology drugs. This increased efficiency results in higher production volumes, reduced production costs, and faster time-to-market for these medications. Technological advancements are also expanding the scalability of manufacturing operations. This is enabling generic oncology drug manufacturers to adjust production volumes more flexibly in response to market demand. Advances in drug formulation and delivery systems are facilitating the development of innovative generic oncology drug products. These technologies have the potential to enhance drug efficacy, reduce side effects, and improve patient compliance, all of which are critical factors in cancer treatment.

Patent Expirations and Cost-Effective Solutions

Patent expirations of several branded oncology drugs are opening opportunities for generic drug manufacturers. When patents for innovative cancer therapies expire, generic manufacturers can enter the market, offering lower-cost alternatives. This competition not only reduces the financial burden on patients but also contributes to healthcare cost containment. The availability of affordable generic oncology drugs ensures that more patients can access treatment, thereby fueling market growth.

Regulatory Support and Approval Pathways

Regulatory bodies are implementing expedited approval pathways for generic oncology drugs. Additionally, various government initiatives and policies encourage the development and manufacturing of generic oncology drugs. These regulatory supports create a favorable environment for generic drug manufacturers. Some regulatory agencies are also offering expedited pathways for the review and approval of generic oncology drugs, especially when there is a need for increased competition or when the drug in question addresses an unmet medical need. These pathways aim to streamline the approval process and facilitate timely market entry. Generic drug manufacturers may face patent challenges from innovator companies seeking to extend their exclusivity. Patent litigation and challenges play a role in the regulatory landscape, as the resolution of patent disputes can influence the timing of generic market entry.

Demand for Personalized Medicine

Advances in genomics and biomarker research are enabling a deeper understanding of the molecular mechanisms underlying cancer. This knowledge allows for the identification of specific genetic alterations and biomarkers associated with different types of cancer, paving the way for the development of targeted therapies. Personalized medicine in oncology often involves the use of targeted therapies designed to selectively inhibit cancer cell growth or survival based on specific molecular characteristics. As branded targeted therapies face patent expirations, generic equivalents are emerging to provide cost-effective alternatives, expanding access to personalized treatment options. The integration of companion diagnostics with personalized medicine is gaining prominence. Companion diagnostics help identify patients who are most likely to respond to a particular treatment, allowing healthcare providers to tailor therapeutic interventions based on the unique genetic profile of patients. Generic oncology drugs can be developed in tandem with companion diagnostics to enhance treatment efficacy.

Healthcare Cost Containment

Governments and healthcare providers are increasingly focusing on cost containment strategies. The use of generic oncology drugs helps in reducing overall healthcare costs, making cancer treatment more sustainable for healthcare systems. The increasing cost of healthcare, including oncology treatments, is becoming unsustainable for many healthcare systems. Moreover, as cancer prevalence rises and innovative therapies emerge, there is a growing need to find cost-effective solutions. Generic oncology drugs, often more affordable than their branded counterparts, play a crucial role in containing overall healthcare expenditures. Governments and healthcare payers are implementing policies promoting the use of generic drugs as a cost-saving measure. Generic substitution, where generic drugs replace branded ones, is actively encouraging to drive down the cost of cancer treatments. In the oncology sector, this can lead to significant savings, especially when dealing with high-cost biologics. The entry of generic oncology drugs creates pricing pressures on branded drugs. As generic alternatives become available, the competition often results in reduced prices for both generic and branded medications. This not only benefits patients but also supports healthcare cost containment initiatives.

Rising Acceptance of Generics

The rising acceptance of generics is supporting the growth of the market. Patients and healthcare systems alike benefit from the economic advantages offered by generic drugs, making essential medications more affordable. Clinical studies and real-world evidence support the notion that generic drugs perform comparably to brand-name drugs. As more evidence accumulates, healthcare professionals and patients become increasingly confident in the effectiveness of generic medications. The availability of generic versions is expanding across various therapeutic areas, ranging from chronic conditions like cardiovascular diseases and diabetes to acute conditions and infectious diseases. A broader generic drug portfolio contributes to increased acceptance as it covers a wide range of medical needs. Apart from this, efforts to enhance health literacy and educate patients about generic medications are increasing acceptance of generics. When patients understand that generics offer the same quality and efficacy as brand-name drugs, they are more likely to accept them as viable treatment options. Furthermore, the emergence of biosimilars, which are highly similar versions of biologic drugs, is receiving regulatory support in various regions. This support boosts confidence in the safety and efficacy of biosimilars, contributing to their acceptance as alternatives to expensive biologics.

Market Consolidation and Strategic Collaborations

Mergers and acquisitions are becoming prominent strategies for companies seeking to consolidate their positions in the generic oncology drugs market. Large pharmaceutical companies often acquire smaller players to gain access to their product portfolios, manufacturing capabilities, or research pipelines. This consolidation enhances operational efficiency and strengthens the overall competitiveness of the acquiring entity. Collaborations and partnerships allow companies to pool resources and expertise, accelerating the research and development (R&D) of generic oncology drugs. By combining knowledge and leveraging strengths, companies can bring new and improved generic formulations to market more efficiently. This is crucial in a sector where timely introduction of cost-effective alternatives is essential.

Generic Oncology Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

North America leads the market, accounting for the largest generic oncology drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

The North America generic oncology drug market is largely driven by the rising prevalence of cancer among the masses due to excessive consumption of alcohol and smoking tobacco products. Governing bodies and healthcare providers in the region are increasingly focused on containing healthcare costs. Generic oncology drugs, known for their cost-effectiveness, align with this goal and are preferred options in various healthcare systems. Stringent regulatory frameworks are governing and streamlining the approval of generic drugs. These regulations ensure the safety, efficacy, and quality of generic oncology drugs, instilling confidence among healthcare professionals and patients. Additionally, technological advancements in pharmaceutical manufacturing, such as continuous manufacturing and automation, are improving the efficiency and cost-effectiveness of producing generic oncology drugs.

Asia Pacific stands as another key region in the market, driven by the increasing investments to improve healthcare infrastructure, increase access to essential medicines, and control healthcare costs. The promotion of generic medications, including oncology drugs, is often a key component of these initiatives to make cancer treatment more affordable. The overall increase in healthcare expenditure in the Asia-Pacific region is leading to a greater emphasis on cost containment. Generic oncology drugs, being more affordable than their branded counterparts, are integral to managing the economic impact of cancer care.

Leading Key Players in the Generic Oncology Drugs Industry:

Key players in the generic oncology drugs market are actively engaged in various strategic initiatives to maintain and expand their market presence. These initiatives include the development and launch of new generic oncology drugs, often following the expiration of patents for branded medications. Additionally, top companies are investing in research and development (R&D) to enhance the quality and efficacy of their generic oncology drug offerings. They are also focusing on cost-efficient manufacturing processes, leveraging technological advancements to improve production efficiency. Marketing efforts emphasize the affordability and accessibility of their products to both patients and healthcare systems. Furthermore, strategic partnerships, collaborations, and acquisitions are becoming prevalent as companies seek to strengthen their portfolios and global reach in this competitive market. Leading companies are actively involving in developing and commercializing generic versions of various oncology medications. They are also prioritizing on biosimilars, including biosimilar versions of oncology drugs and involving in the development and commercialization of cost-effective alternatives to branded oncology biologics.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided.

Key Questions Answered in This Report

  • 1. What was the size of the global generic oncology drugs market in 2023?
  • 2. What is the expected growth rate of the global generic oncology drugs market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global generic oncology drugs market?
  • 4. What are the key factors driving the global generic oncology drugs market?
  • 5. What are the key regions in the global generic oncology drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Generic Drug Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Market Breakup by Region
  • 5.4 Market Forecast

6 Global Generic Oncology Drug Market

  • 6.1 Market Overview
  • 6.2 Market Trends
  • 6.3 Impact of COVID-19
  • 6.4 Top Generic Oncology Drugs
  • 6.5 Price Analysis
  • 6.6 Market Forecast
  • 6.7 SWOT Analysis
    • 6.7.1 Overview
    • 6.7.2 Strengths
    • 6.7.3 Weaknesses
    • 6.7.4 Opportunities
    • 6.7.5 Threats
  • 6.8 Value Chain Analysis
    • 6.8.1 Research and Development
    • 6.8.2 Manufacturing
    • 6.8.3 Marketing
    • 6.8.4 Distribution
  • 6.9 Porter's Five Forces Analysis
    • 6.9.1 Overview
    • 6.9.2 Bargaining Power of Buyers
    • 6.9.3 Bargaining Power of Suppliers
    • 6.9.4 Degree of Competition
    • 6.9.5 Threat of New Entrants
    • 6.9.6 Threat of Substitutes
    • 6.9.7 Regulations in the Generics Industry
  • 6.10 Key Market Drivers and Success Factors

7 Global Generic Oncology Drug Market: Performance of Key Regions

  • 7.1 North America
  • 7.2 Europe
  • 7.3 Asia Pacific
  • 7.4 Middle East and Africa
  • 7.5 Latin America

8 Global Generic Oncology Drug Market: Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Market Breakup by Key Players
  • 8.3 Key Player Profiles

9 Generic Oncology Drug Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Detailed Process Flow (Tablets)
  • 9.3 Detailed Process Flow (Injectable)
  • 9.4 Various Types of Unit Operations Involved
  • 9.5 Mass Balance and Raw Material Requirements

10 Project Details, Requirements and Costs Involved

  • 10.1 Land Requirements and Expenditures
  • 10.2 Construction Requirements and Expenditures
  • 10.3 Plant Machinery
  • 10.4 Machinery Pictures
  • 10.5 Raw Material Requirements and Expenditures
  • 10.6 Packaging Requirements and Expenditures
  • 10.7 Transportation Requirements and Expenditures
  • 10.8 Utility Requirements and Expenditures
  • 10.9 Manpower Requirements and Expenditures
  • 10.10 Other Capital Investments

11 Loans and Financial Assistance

12 Project Economics

  • 12.1 Capital Cost of the Project
  • 12.2 Techno-Economic Parameters
  • 12.3 Product Pricing and Margins Across Various Levels of the Supply Chain
  • 12.4 Taxation and Depreciation
  • 12.5 Income Projections
  • 12.6 Expenditure Projections
  • 12.7 Financial Analysis
  • 12.8 Profit Analysis

List of Figures

  • Figure 1: Global: Generic Drug Market: Major Drivers and Challenges
  • Figure 2: Global: Generic Drug Market: Sales Value Trends (in Billion US$), 2018-2023
  • Figure 3: Global: Generic Drug Market Forecast: Sales Value Trends (in Billion US$), 2024-2032
  • Figure 4: Global: Generic Drug Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Generic Oncology Drug Industry Overview
  • Figure 6: Global: Generic Oncology Drug Market: Sales Value Trends (in Billion US$), 2018-2023
  • Figure 7: Global: Generic Oncology Drug Market Forecast: Sales Value Trends (in Billion US$), 2024-2032
  • Figure 8: Global: Generic Oncology Drug Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Generic Oncology Drug Industry: SWOT Analysis
  • Figure 10: Global: Generic Oncology Drug Industry: Value Chain Analysis
  • Figure 11: Global: Generic Oncology Drug Industry: Porter's Five Forces Analysis
  • Figure 12: North America: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 13: Asia Pacific: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 14: Europe: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 15: Latin America: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 16: Middle East and Africa: Generic Oncology Drug Market (in Million US$), 2018, 2024 & 2032
  • Figure 17: Generic Oncology Drug Industry: Profit Margins at Various Levels of the Supply Chain
  • Figure 18: Generic Oncology Drug Manufacturing: Production Cost Breakup (in %)
  • Figure 19: Generic Oncology Drug Manufacturing Plant: Detailed Process Flow
  • Figure 20: Generic Oncology Drug Manufacturing Process: Conversion Rate of Feedstocks
  • Figure 21: Generic Oncology Drug Manufacturing Plant: Proposed Plant Layout
  • Figure 22: Generic Oncology Drug Manufacturing Plant: Breakup of Capital Costs (in %)

List of Tables

  • Table 1: Global: Generic Drug Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Generic Drug Market Forecast: Breakup by Region, 2024-2032
  • Table 3: Global: Generic Oncology Drug Market: Key Industry Highlights, 2023 and 2032
  • Table 4: Generic Oncology Drug Manufacturing Plant: Costs Related to Land and Site Development (in US$)
  • Table 5: Generic Oncology Drug Manufacturing Plant: Costs Related to Civil Works (in US$)
  • Table 6: Generic Oncology Drug Manufacturing Plant: Costs Related to Machinery Unit (in US$)
  • Table 7: Generic Oncology Drug Manufacturing Plant: Raw Material Requirements
  • Table 8: Generic Oncology Drug Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
  • Table 9: Generic Oncology Drug Manufacturing Plant: Costs Related to Other Capital Investments (in US$)
  • Table 10: Details of Financial Assistance Offered by Financial Institutions
  • Table 11: Generic Oncology Drug Manufacturing Plant: Capital Costs (in US$)
  • Table 12: Generic Oncology Drug Manufacturing Plant: Techno-Economic Parameters
  • Table 13: Generic Oncology Drug Manufacturing Plant: Taxation and Depreciation
  • Table 14: Generic Oncology Drug Manufacturing Plant: Income Projections (in US$)
  • Table 15: Generic Oncology Drug Manufacturing Plant: Expenditure Projections (in US$)
  • Table 16: Generic Oncology Drug Manufacturing Plant: Cash Flow Analysis Without Considering the Income Tax Liability
  • Table 17: Generic Oncology Drug Manufacturing Plant: Cash Flow Analysis on Considering the Income Tax Liability
  • Table 18: Generic Oncology Drug Manufacturing Plant: Profit and Loss Account